Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/ Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion s ML-enabled Operating System for the potential treatment of C. difficile.
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
SALT LAKE CITY, April 16, 2021 /PRNewswire/ Recursion Pharmaceuticals, Inc. ( Recursion or we ) today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Recursion, are expected to be $436.4 million, excluding any exercise of the underwriters option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol RXRX and the offering is expected to close on April 20, 2021, subject to customary closing conditions. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an
Recursion Pharmaceuticals Announces Pricing of Initial Public Offering prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.